Mireia Vila-Margeli
Badalona, CT 08916, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression.
Journal: Cancer drug resistance (Alhambra, Calif.)
Published: October 29, 2024
Elacestrant in Women with Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 30, 2024
Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 28, 2023
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 18, 2022
SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer.
Journal: Frontiers in oncology
Published: December 06, 2020
Influence of the 2019-novel coronavirus pandemic on the management of breast cancer
Journal: Clinica e investigacion en ginecologia y obstetricia
Published: August 25, 2020
Advantages of preoperative localization and surgical resection of metastatic axillary lymph nodes using magnetic seeds after neoadjuvant chemotherapy in breast cancer.
Journal: Surgical oncology
Published: May 23, 2020
Use of denosumab in a dialysis patient with bone metastases from breast cancer and hepatorenal polycystic disease: a case report.
Journal: Anti-cancer drugs
Published: January 28, 2016
Primary Hormone Therapy in Elderly Women with Hormone-Sensitive Locoregional Breast Cancer: Endocrine Therapy Alone Is a Reasonable Alternative in Selected Patients.
Journal: Breast care (Basel, Switzerland)
Published: December 10, 2015
Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 30, 2015
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 05, 2013
Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 08, 2013
Showing 1-12 of 12
Last Updated: 09/26/2026